On Demand 2025 Thursday Program

You can earn up to 6.5 AMA PRA Category 1 Credit(s)TM.

Price: FREE for meeting attendees who purchased a ticket to the Thursday Program, otherwise $99 members, $125 non-members

This educational event, Spotlight on Allergic Conditions of the Skin, is designed to explore the latest advancements, diagnostic techniques, and management strategies for a variety of allergic skin disorders. This comprehensive program will provide learners with expert insights and practical knowledge applicable to clinical practice.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Objective 1:
Evaluate potential underlying causes of idiopathic angioedema, differentiate between truly idiopathic cases and those with identifiable (but lesser known) triggers, and develop evidence-based management strategies to optimize patient outcomes. Analyze the role of genetic variants and associated biomarkers in the pathophysiology of angioedema and assess how these factors influence the selection of targeted therapeutic approaches.
Objective 2:
Implement a stepwise approach to diagnosing and managing histaminergic and non-histaminergic angioedema, including selecting appropriate therapies based on underlying mechanisms and patient-specific factors. Evaluate the importance of measuring quality of life in patients with CSU, select appropriate QoL assessment tools, and integrate them into personalized treatment plans to improve patient outcomes.
Objective 3:
Apply evidence-based strategies for the diagnostic work-up of CSU, interpret the relevance of biomarkers in predicting disease outcomes, and incorporate these insights into the selection of current and emerging therapies. Identify and evaluate emerging treatments for CSU, understand their mechanisms of action, and incorporate these advancements into clinical practice to enhance patient care.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance
  • 6.50 CBRN
Course opens: 
11/26/2025
Course expires: 
11/25/2028
Cost:
$125.00
Rating: 
0

Kristin C. Sokol, MD, MS, MPH, FACAAI
Jonathan A. Bernstein, MD, FACAAI
Marc A. Riedl, MD, MS
Aleena Banerji, MD
Dawn Merritt, DO
David A Khan, MD, FACAAI
Martin Metz, MD, PhD
Timothy Berger, MD
Anil Nanda, MD, FACAAI
Peter A. Lio, MD
Mark Boguniewicz, MD, FACAAI
Clinton P. Dunn, MD, FACAAI
Robert Sporter, MD, FACAAI
Ana Maria Copaescu, MD, PhD
Luz S. Fonacier, MD, FACAAI

Available Credit

  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance
  • 6.50 CBRN

Price

Cost:
$125.00
Please login or create an account to take this course.